83 results about "Platelet activation" patented technology

An implantable pump system is provided, suitable for use as a left ventricular assist device (LVAD) system, having an implantable pump, a battery, a controller, and a programmer. The implantable pump includes a flexible membrane coupled to an actuator assembly via a skirt that extends toward the inlet of the pump and curves to guide blood toward the outlet. The actuator assembly is magnetically engageable with electromagnetic coils, so that when the electromagnetic coils are energized, the actuator assembly causes wavelike undulations to propagate along the flexible membrane to propel blood from the inlet, across the skirt, and through the outlet of the implantable pump. The controller may be programmed by a programmer to operate at frequencies and duty cycles that mimic physiologic flow rates and pulsatility while operating in an efficient manner that avoids thrombus formation, hemolysis and / or platelet activation.

The invention discloses a preparation method of a composite spray for improving the hemostatic ability of a wound part, the composite spray comprises a liquid A and a liquid B. The liquid B is a sodium alginate aqueous solution, a preparation method of the solution A comprises the following steps: 1, dissolving a lipopeptide conjugate, cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidylserine and dimethyl sulfoxide in a chloroform-methanol mixed solution to obtain a mixed system; 2, preparing the mixed system into a precursor solution by utilizing a film hydration method; 3, adding calcium chloride into the precursor solution, and reacting in a dark place to obtain a solution A; a precursor solution is designed according to the function of natural platelets, the function of the precursor solution is equivalent to that of nano platelets, the precursor solution is matched with sodium alginate, adverse effects on a blood coagulation system caused by fibrin degradation, platelet activation capability reduction and the like of a wound part due to blood loss can be relieved in a targeted manner, and the preparation has the advantages of rapid hemostasis, good biological activity, no toxic or side effects and the like. And the wound healing is rapid.

The invention discloses a double-layer small-caliber artificial blood vessel with an in-situ modified anticoagulant coating and a preparation method. The double-layer small-caliber artificial blood vessel with the in-situ modified anticoagulant coating is prepared by combining a coaxial dry-jet wet spinning technology and a polydopamine-heparin modification technology. According to the obtained double-layer small-caliber blood vessel, the outer layer provides enough mechanical strength and structural stability, the inner layer has good hydrophilicity and excellent anticoagulation function through polydopamine in-situ grafting heparin, activation of platelets and adhesion of blood cells are reduced, formation of short-term acute thrombus is prevented, and the endothelialization process of the small-caliber blood vessel is promoted; according to the method provided by the invention, the manufacturing and surface modification process of the small-caliber artificial blood vessel is simplified, additional procedures such as secondary processing are avoided, the modification position and the grafting amount are controllable, the experimental stability is high, and a convenient and efficient preparation technical idea is provided for developing the small-caliber artificial blood vessel.

In an illustrative embodiment, methods and system for increasing coagulation potential and / or triggering a higher platelet activation rate in a subject via auricular neurostimulation include contacting skin of the subject with one or more therapeutic electrodes, each electrode positioned in a respective region of nerve structures of the auriculotemporal nerve (ATN), nerve structures connected to the ATN, nerve structures of the auricular branch of the vagus nerve (ABVN), or nerve structures connected to the ABVN, applying, to the electrodes, one or more stimulation patterns.

An implantable pump system is provided, including an implantable blood pump suitable for use as a partial support assist device, the system further including an extracorporeal battery and a controller coupled to the implantable pump, and a programmer selectively periodically coupled to the controller to configure and adjust operating parameters of the implantable pump. The implantable pump includes a flexible membrane coupled to an electromagnetic actuator including a magnetic assembly and electromagnetic assembly, so that when the electromagnetic assembly is energized, the electromagnetic assembly causes wavelike undulations to propagate along the flexible membrane to propel blood through the implantable pump. The controller may be programmed by a programmer to operate at frequencies and duty cycles that mimic physiologic flow rates and pulsatility while operating in an efficient manner that avoids thrombus formation, hemolysis and / or platelet activation.

The invention provides an application of Cath-HG in preparation of a medicine for preventing and / or treating psoriasis. Experiments prove that Cath-HG has a good curative effect on an imiquimod-induced mouse psoriasis model, can improve skin injury, reduce PASI score, reduce inflammatory cytokine mRNA level, reduce spleen coefficient, recover the number of platelets and neutrophils, inhibit platelet activation and platelet-neutrophil compound formation, reduce neutrophil infiltration and activation, and can be used for treating psoriasis. The release of extracellular traps of neutrophils is inhibited.

The invention belongs to the technical field of biological medicines, and relates to a Rubicon permeable membrane peptide and application thereof. Specifically, the permeable membrane peptide fragment sequence is designed on the basis of an amino acid sequence of interaction of Rubi protein and Btk, and seven permeable membrane sections of arginine are connected to the tail end of the permeable membrane peptide fragment sequence through disulfide bonds. Immunofluorescence experiments prove that the peptide fragment can efficiently penetrate a platelet membrane to enter cells, and co-immunoprecipitation experiments prove that the peptide fragment has strong affinity with Btk. Platelet aggregation experiments show that the peptide fragment can significantly inhibit platelet activation under collagen stimulation. In an animal model, the peptide fragment is injected before instantaneous middle cerebral artery occlusion or reperfusion of a mouse, and ischemia-reperfusion injury can be effectively relieved. The invention provides a novel potential drug candidate for treating thrombotic diseases and ischemia-reperfusion injury.

This invention discloses a method for preparing a composite spray that improves hemostasis at wound sites. The composite spray includes solution A and solution B, where solution B is an aqueous solution of sodium alginate. The preparation method of solution A includes: 1. Dissolving a lipopeptide conjugate, cholesterol, distearylphosphatidylcholine, distearylphosphatidylserine, and dimethyl sulfoxide in a chloroform-methanol mixed solution to obtain a mixed system; 2. Preparing a precursor solution from the mixed system using a thin-film hydration method; 3. Adding calcium chloride to the precursor solution and reacting it in the dark to obtain solution A. This invention designs the precursor solution based on the function of natural platelets, and its function is equivalent to that of nanoplatelets. Combined with sodium alginate, it can specifically alleviate the adverse effects on the coagulation system caused by blood loss, such as fibrin degradation and reduced platelet activation, at wound sites. It has the characteristics of rapid hemostasis, good bioactivity, and rapid wound healing.

The utility model discloses a hemostasis assist device for vascular surgery, which relates to the technical field of medical instruments, and comprises a fixing mechanism, a vascular surgery hemostasis mechanism is arranged in the fixing mechanism, the vascular surgery hemostasis mechanism comprises a knob, and the bottom of the knob is fixedly connected with a threaded column. According to the hemostasis mechanism for the vascular surgery department, during hemostasis, the periphery of a wound can be heated through the heating block across the replacement pad, the temperature of the periphery of the wound reaches 37-42 DEG C, activation of platelets can be accelerated to a certain extent at the temperature, energy metabolism of the platelets is accelerated within the temperature range, and the blood circulation is accelerated. The increase of the concentration of calcium ions in the blood platelets is an important signal of platelet activation, and the increased concentration of the calcium ions can promote the activation of glycoprotein receptors on platelet membranes, so that the binding capacity of the blood platelets and fibrinogen is enhanced, the aggregation of the blood platelets is accelerated, and the hemostasis speed is accelerated.

Synthetic hemocompatible vascular grafts manufactured from polyvinyl alcohol-based biomaterials containing crystalline segments of polyvinyl alcohol, which are long-term fully functioning vascular grafts that provide no activity towards immune systems in recognizing surfaces as foreign bodies that would normally lead to fibrosis, platelet activation and subsequent thrombi formation, and thus occlusion of the grafts.

The present invention discloses the use of HMG-CoA and its pharmaceutically acceptable salts for preparing a platelet preservative. The present invention has confirmed that adding HMG-CoA or its pharmaceutically acceptable salts to platelets to be preserved can effectively alleviate platelet activation and apoptosis, while prolonging the in vivo survival period of platelets after platelet transfusion and protecting the hemostatic function of platelets.

The application discloses a multifunctional blood vessel stent with a negative Poisson's ratio structure and a preparation method thereof, relates to the technical field of medical devices, and comprises the construction of a blood vessel stent model with a negative Poisson's ratio structure, selective laser melting additive manufacturing, chemical polishing treatment and surface biomimetic modification treatment. The stent can better adapt to the deformation of a blood vessel by virtue of the negative Poisson's ratio characteristic, reduces incompatibility caused by different deformation steps, the structure of the stent is round and smooth, blood flow turbulence and vortex at sharp corners of a traditional stent can be effectively avoided, the hemodynamic performance is improved, the risk of platelet activation and thrombosis is reduced, a surface gradient coating is prepared, multi-mechanism synergy is realized, and the formation of an endothelial layer on the surface of the stent is facilitated.

Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

The invention discloses application of a marker to preparation of a kit for diagnosing chronic obstructive pulmonary diseases. According to the application disclosed by the invention, the accuracy of diagnosing the chronic obstructive pulmonary disease by using (R)-3-hydroxytetradecanoic acid alone or in combination with the azelayl platelet activating factor is relatively high; on the basis of combination of (R)-3-hydroxytetradecanoic acid and an azelayl platelet activating factor, the compound is prepared. The compound can be further combined with one or two of 1-hexadecyl-2-(5-oxovaleryl)-sn-glycerol-3-phosphorylcholine, 1-O-hexadecyl-SN-glycerol-3-choline phosphoric acid, lauroyl-L-carnitine and beta-acetyl-gamma-O-alkyl-L-alpha-phosphatidylcholine to be used for diagnosing the chronic obstructive pulmonary disease. Therefore, a diagnostic kit for diagnosing the chronic obstructive pulmonary disease can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.

The invention belongs to the technical field of biological medicine, and relates to an anticoagulant, in particular to an anticoagulant for a high-precision animal blood cell analyzer and application of the anticoagulant in leukocyte classification. The anticoagulant comprises a buffer and anticoagulation matrix component and an active component, wherein in every 100 mL of the anticoagulant, the buffer and anticoagulation matrix component formula comprises 1.5 to 2 g of citrate, 0.3 to 0.5 g of citric acid and 0.15 to 0.20 g of EDTA-K2 (Ethylene Diamine Tetraacetic Acid), and the active components comprise 0.08 to 0.10 g of low molecular weight enzymolysis carboxymethyl chitosan, 1.0 to 1.2 g of hydroxypropyl-beta-cyclodextrin, 10 to 15 mg of dipyridamole and 8 to 10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and leukocyte morphological deformation, realizes accurate identification in leukocyte five-classification, has a classification accuracy rate of 98%, and is suitable for veterinary clinical hematology examination and animal epidemic disease monitoring.

The invention discloses a macrophage-platelet targeting delivery system carrying genes and mitochondria as well as a preparation method and application of the macrophage-platelet targeting delivery system. The platelet loaded with the PPAR gamma gene nano-composite is covalently linked to the surface of macrophage through a click chemical reaction, and a novel cell composite carrier is constructed. According to the system, the natural chemotaxis of macrophages to an injured part is fully utilized to realize precise targeting, and PPAR gamma genes and functional mitochondria are synchronously released through platelet activation in an injured microenvironment, so that the energy metabolism and lipid homeostasis of the macrophages are cooperatively regulated and controlled, the cellular burial function of the macrophages is effectively recovered, and tissue repair and regeneration are promoted. Experimental results show that the delivery system is reliable in preparation method and high in targeting efficiency, axon regeneration, myelin sheath repair and motor function recovery can be remarkably promoted in a spinal cord injury model, and a brand-new synergistic treatment strategy is provided for tissue injury repair.

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

An implantable pump system is provided, suitable for use as a left ventricular assist device (LVAD) system, having an implantable pump, a battery, a controller, and a programmer. The implantable pump includes a flexible membrane coupled to an actuator assembly via a skirt that extends toward the inlet of the pump and curves to guide blood toward the outlet. The actuator assembly is magnetically engageable with electromagnetic coils, so that when the electromagnetic coils are energized, the actuator assembly causes wavelike undulations to propagate along the flexible membrane to propel blood from the inlet, across the skirt, and through the outlet of the implantable pump. The controller may be programmed by a programmer to operate at frequencies and duty cycles that mimic physiologic flow rates and pulsatility while operating in an efficient manner that avoids thrombus formation, hemolysis and / or platelet activation.

The application belongs to the technical field of biological medicine, and relates to an anticoagulant and application thereof in white blood cell classification for high-precision animal blood cell analyzers. The anticoagulant comprises two parts of buffer and anticoagulant matrix components and active components. In the anticoagulant, the buffer and anticoagulant matrix component formula comprises 1.5-2 g of citrate, 0.3-0.5 g of citric acid and 0.15-0.20 g of EDTA-K2 per 100 mL of the anticoagulant, and the active component comprises 0.08-0.10 g of low-molecular enzymatic hydrolysis carboxymethyl chitosan, 1.0-1.2 g of hydroxypropyl-beta-cyclodextrin, 10-15 mg of dipyridamole and 8-10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and white blood cell morphological deformation, accurately identifies in white blood cell five classification, and has a classification accuracy as high as 98%, and is suitable for veterinary clinical hematology examination and animal disease monitoring.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

The invention discloses an application of a TBOA analogue in preparation of a kit for testing platelet stress self-regulating force, and the platelet stress self-regulating force is reflected by the aggregation degree of platelets after being intervened by the TBOA analogue. The application focuses on a new mechanism of platelet activation, that is, when platelets are stimulated by activators such as thrombin, normal reactions of activation and aggregation are driven and maintained by adjusting uptake of glutamic acid by EAATs. Due to the clear action mechanism, the application can provide indexes and methods with higher specificity in diagnosis, treatment and prognosis evaluation of thrombotic diseases, and the pertinence is extremely high. According to the application, the influence of the TBOA analogue on the platelet aggregation degree is utilized to test the stress self-regulating force of the platelet, and new clinical application of the TBOA analogue is developed.

In an illustrative embodiment, methods and system for increasing coagulation potential and / or triggering a higher platelet activation rate in a subject via auricular neurostimulation include contacting skin of the subject with one or more therapeutic electrodes, each electrode positioned in a respective region of nerve structures of the auriculotemporal nerve (ATN), nerve structures connected to the ATN, nerve structures of the auricular branch of the vagus nerve (ABVN), or nerve structures connected to the ABVN, applying, to the electrodes, one or more stimulation patterns.

The present invention discloses engineered platelets carrying platelet activation inhibitor nanoparticles, a preparation method and application thereof, which belongs to the field of pharmaceutical technology and relates to a preparation method of engineered platelets carrying ticagrelor nanoparticles and its therapeutic use in malignant solid tumors. The preparation of the engineered platelets described in the present invention includes the steps of extracting and purifying platelets, preparing gelatin nanoparticles loaded with platelet activation inhibitors, anchoring the nanoparticles to the outer surface of platelets, etc. The engineered platelets of the present invention are targeted to reach the tumor site by recruiting tumor-associated platelets in the body, and specifically respond to matrix metalloproteinases to release the carried platelet activation inhibitor, thereby inhibiting the activation of platelets in the tumor microenvironment, enhancing tumor vascular leakage, alleviating the immunosuppressive microenvironment, and effectively enhancing the effects of chemotherapy and immunotherapy.

The invention discloses a preparation method of a silk conical artificial blood vessel with anticoagulation / endothelialization promotion functions, which comprises the following steps: preparing an artificial blood vessel for intracavity isolation through silk and polyester yarns, and successfully constructing a phosphorylcholine / heparin bionic functional coating on the surface of the blood vessel by using dopamine hydrochloride and hexamethylenediamine. According to the method, phosphorylcholine / heparin is combined with surface coating modification, and a novel intracavitary isolated blood vessel with excellent biological functions and mechanical properties is constructed. The structure of the artificial blood vessel is more matched with the shape of the inner wall of the blood vessel, blood flow distribution and tissue regeneration are facilitated, the anticoagulant property and endothelialization ability of the artificial blood vessel are effectively improved through the phosphorylcholine / heparin coating, protein adsorption and platelet activation can be remarkably reduced, the blood coagulation cascade reaction can be blocked, endothelial cell adhesion and proliferation can be accelerated, and the risk of acute thrombus after operation can be reduced. The method provides a new technical path for design and functionalization of the conical artificial blood vessel in the intracavitary isolation operation, and has important clinical application prospects.

The present invention relates to the technical field of the biopharmaceutical industry, and specifically to a Platycladus orientalis leaf extract and a preparation method thereof, comprising the following raw materials: a modified Platycladus orientalis leaf extract, a modified total saponin of Panax notoginseng, Panax notoginseng, fibrin, chitosan, iron oxide, glycerol, and a modified spinach solution. In the present invention, the modified Platycladus orientalis leaf extract, the modified total saponin of Panax notoginseng, and the modified spinach solution work together through a synergistic effect. The modified Platycladus orientalis leaf extract contains a relatively high amount of volatile oil, which can stimulate platelet aggregation and promote the release of coagulation factors. The modified total saponin of Panax notoginseng can inhibit excessive platelet activation and aggregation, preventing thrombosis. The modified Platycladus orientalis leaf extract and the modified total saponin of Panax notoginseng can jointly promote platelet aggregation and the release of coagulation factors to accelerate blood coagulation. The modified spinach solution promotes the synthesis and release of coagulation factors by providing vitamin K, thereby accelerating blood coagulation. The three form a dynamic equilibrium system, which promotes blood coagulation through a synergistic effect, achieving a hemostatic effect.

The present invention relates to the field of biomedicine technology, and specifically to a reagent combination, a kit and a detection method for detecting platelet activation marker PAC‑1. The reagent combination includes: a first detection probe, a second detection probe, a third detection probe and a fourth detection probe; the first detection probe is at least formed by coupling DNA1 and PAC‑1 antibody 1; the second detection probe is at least formed by coupling PAC‑1 antibody 2 and DNA2; the third detection probe is DNA3 labeled with a fluorescent molecule; the fourth detection probe is an antioxidant bound to a carrier molecule. When using the reagent combination or kit of the present invention to detect PAC‑1, the cost is low, and whole blood can be used for detection, which is convenient and quick while avoiding artificial platelet activation in in vitro samples. In addition, the detection operation process is simple, the overall detection time is short, and it is suitable for the actual needs of clinical detection of PAC‑1.

The present application relates to a kind of preservative solution for prolonging the in vitro storage period of platelet and its preparation method, containing baicalin 4.50~6.00g, baicalein 3.00~3.40g, sodium citrate 1.50~2.00g, citric acid 0.20~0.50g, glucose 7.90~8.50g per liter of preservative solution, and the remaining component is distilled water.The preservative solution of the present application adds a certain proportion of baicalin and baicalein, and the composition has a synergistic effect on inhibiting platelet activation, protection and inhibition of platelet aggregation, can prolong the in vitro platelet normal temperature storage time, and the normal temperature storage time can reach 16d.

The present invention relates to the field of pharmaceutical compositions and the treatment and / or prevention of medical conditions including thrombosis or atherosclerosis associated with pathological platelet activation. The present invention further relates to cystic fibrosis transmembrane conductance regulator (CFTR) modulators used in the treatment and / or prevention of medical conditions including thrombosis or medical conditions including atherosclerosis and pathological platelet activation in human subjects. The present invention further relates to medical uses and corresponding therapeutic methods of administering CFTR modulators such as ivacaftor in the treatment and / or prevention of medical conditions including pathological platelet activation, adhesion and / or aggregation. In a further aspect, the present invention relates to pharmaceutical compositions comprising CFTR modulators such as ivacaftor.

The invention discloses application of a PAS-Bu solution to preparation of a platelet preservative. The PAS-Bu solution is prepared from sodium butyrate, glucose, sodium chloride, potassium chloride, magnesium chloride, sodium citrate and sodium phosphate. The invention proves that the PAS-Bu solution can effectively relieve activation and apoptosis of platelets, maintain the young state of the platelets, prolong the storage life of the platelets and protect the hemostasis function of the platelets.

The present invention relates to a method for analyzing platelet activation induced by antibodies directed against the polyanion-modified platelet factor 4 (PF4), preferably directed against the PF4 / heparin complex, as well as to a method of in vitro diagnosis of heparin-induced thrombocytopenia or of a diagnosis of exclusion of a heparin-induced thrombocytopenia in a patient, comprising specific steps.